Inventor · disambiguated record
John Frederick Boylan
Also filed as: BOYLAN JOHN · BOYLAN JOHN F · BOYLAN JOHN FREDERICK
18 granted patents·12 pending applications·65 citations·filing 2001–2023
92Inventor score
Files withSIGNAL PHARM LLC9BOYLAN JOHN FREDERICK8AMGEN INC3ARROWHEAD PHARMACEUTICALS INC3SIGNAL PHARMACEUTICAL LLC3
Top patents by PatentIndex Score
30 records- 0197US9512124B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·32 cites·60 claims
- 0296US9737541B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Aug 22, 2017·12 cites·52 claims
- 0385US10940152B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted Mar 9, 2021·1 cites·27 claims
- 0484US10646493B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted May 12, 2020·1 cites·20 claims
- 0584US2023158035A1Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2023·Application pending·0 cites
- 0683US9428509B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted Aug 30, 2016·6 cites·32 claims
- 0783US9346812B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2014·Granted May 24, 2016·6 cites·30 claims
- 0875US11590139B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2021·Granted Feb 28, 2023·0 cites·52 claims
- 0973US8741889B2Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitorBOYLAN JOHN FREDERICK·Filed 2012·Granted Jun 3, 2014·3 cites·15 claims
- 1072US11920134B2Compositions and methods for inhibiting expression of RRM2 genesARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Mar 5, 2024·0 cites·21 claims
- 1170US6881542B1Serine threonine kinase member, h2520-59AMGEN INC·Filed 2001·Granted Apr 19, 2005·3 cites·17 claims
- 1269US8946176B2Compositions and methods for inhibiting expression of RRM2 genesBOYLAN JOHN FREDERICK·Filed 2011·Granted Feb 3, 2015·1 cites·18 claims
- 1368US10619160B2Compositions and methods for inhibiting expression of RRM2 genesARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Apr 14, 2020·0 cites·21 claims
- 1462US2015113670A1Compositions and Methods for Inhibiting Expression of RRM2 GenesARROWHEAD RES CORP·Filed 2014·Application pending·0 cites
- 1561US9938531B2Compositions and methods for inhibiting expression of RRM2 genesARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Apr 10, 2018·0 cites·18 claims
- 1655US2006067926A1Novel serine threonine kinase member, h2520-59AMGEN INC·Filed 2005·Application pending·0 cites
- 1753US9795607B2Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARMACEUTICAL LLC·Filed 2016·Granted Oct 24, 2017·0 cites·33 claims
- 1852US2012225860A1Method for administration of a gamma secretase inhibitorBOYLAN JOHN FREDERICK·Filed 2012·Application pending·0 cites
- 1951US7029892B1Serine threonine kinase member, h2520-59AMGEN INC·Filed 2002·Granted Apr 18, 2006·0 cites·11 claims
- 2051US2014357620A1Method for administration of a gamma secretase inhibitorHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 2146US2013072543A1Compounds and Compositions for Nucleic Acid Formulation and DeliveryBOYLAN JOHN FREDERICK·Filed 2012·Application pending·0 cites
- 2246US2009181944A1Method for cancer therapyBOYLAN JOHN FREDERICK·Filed 2009·Application pending·0 cites
- 2345US2013079383A1Lipid Compounds Targeting VLA-4BOYLAN JOHN FREDERICK·Filed 2012·Application pending·0 cites
- 2444US8309299B2Combination therapy and method for assessing resistance to treatmentBOYLAN JOHN FREDERICK·Filed 2011·Granted Nov 13, 2012·0 cites·11 claims
- 2542US2017173024A1Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereofSIGNAL PHARM LLC·Filed 2017·Application pending·0 cites
- 2639US2003036183A1Serine threonine kinase member, h2520-40Filed 2002·Application pending·0 cites
- 2738US10576085B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Mar 3, 2020·0 cites·22 claims
- 2838US9623028B2Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereofSIGNAL PHARM LLC·Filed 2015·Granted Apr 18, 2017·0 cites·18 claims
- 2938US2011112176A1Compositions and methods for inhibiting expression of kif10 genesBOYLAN JOHN FREDERICK·Filed 2010·Application pending·0 cites
- 3036US2012114638A1Combination therapyBOYLAN JOHN·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Frederick Boylan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →